Genmab, a renowned biotech company, has seen a ton of market activity recently. Despite suffering a slump after a significant move, a $1.8 billion acquisition of
ProfoundBio, the company is taking assertive measures such as advancing its share
buy-back program and expanding share capital plans. Even as shares have hit a four-year low, Genmab remains a well-regarded investment, with a 'Buy' rating reaffirmed by
HC Wainwright and a purchase of over 8000 shares by
PNC Financial Services Group Inc. While moving towards the future, Genmab has exciting developments in the pipeline, including a focus on ovarian cancer drugs with the acquisition of ProfoundBio and boasting strong Q1 sales of its drug,
DARZALEX. Despite short-term downturns, investors have seen a commendable 82% return in the past five years. Nevertheless, due diligence is vital as financial prospects remain attractive, but risks persist with a recent price drop and significant sell-offs by companies such as Wellington Management Group LLP and Franklin Resources Inc.
Genmab Stocks News Analytics from Wed, 02 Oct 2019 07:00:00 GMT to Sat, 22 Jun 2024 19:16:23 GMT -
Rating 2
- Innovation -3
- Information 6
- Rumor 4